A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

研究人员选择研究Semaglutide作为潜在治疗方法，因为这一类药物有助于减少MASH患者的脂肪和肝脏疤痕。Newsome教授此前在《柳叶刀》和《新英格兰医学杂志》上发表的小规模积极研究表明，使用Semaglutide治疗MASH对患者有益。

A new study published in the New England Journal of Medicine reveals that medications widely used for diabetes and obesity ...

代谢相关脂肪性肝病（MASLD）诊疗面临困境，缺乏可靠诊断生物标志物和有效治疗策略。研究人员通过分析 GEO 数据库数据，经多方法筛选出 5 个关键基因（UBD、STMN2、LYZ、DUSP8、GPR88）。这为 MASLD 诊断和治疗提供新思路。

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition ...

2025年第34届亚太肝病学会年会（APASL 2025）于3月26 - 30日在北京国家会议中心隆重召开。本次大会以“多元合作 ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

肝细胞癌（HCC）死亡率高，代谢功能障碍相关脂肪性肝炎（MASH）是其重要诱因，但相关信号及治疗手段有限。研究人员探究 STE20 型激酶 STK25 在 MASH 相关 HCC 中的作用，发现抑制 STK25 可减缓 HCC 发展，为防治提供新策略。

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

The reserarchers found that a weekly dose of semaglutide was effective at treating Metabolic Dysfunction-Associated ...